What You Control: Your Microbiome, Diet, Stress, & Melanoma

14 April 2022 In Science

Every day, we hear from patients who want to know what, if anything, they can do to have the best health outcomes possible. For people facing melanoma, it’s common to feel overwhelmed and out of control with everything that a melanoma diagnosis and treatment entail. Yet, how one faces those challenges, can make a big difference. MRA-funded investigator Lorenzo Cohen, PhD is working hard to help patients understand the pivotal role of the microbiome, diet, stress — and their melanoma — on treatment outcomes.

Read More

Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment

It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.

Read More

MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma

18 March 2022 In News, Science, Treatment

The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.

Read More

Recordings from MRA's 2022 Patient Forum

16 March 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment

MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together hundreds of melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.

Read More

Testing AI in the Melanoma: From Promise to Action

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 8 March 2022 In Prevention, Science

If you browse through your phone’s app store, you’ll find dozens of apps promising to help determine if a mole you’ve been staring at is cancerous or not based on the power of AI. While a great goal, none of these apps have earned approval from the Food and Drug Administration (FDA). However, to do so, apps — and the algorithms that they rely on — will need to be rigorously tested in the real world and across diverse populations. This is exactly where Dr. Novoa’s research is aimed.

Read More

Melanoma Free & Living Scan-to-Scan

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 4 March 2022 In Melanoma Stories

In 2007, while staining her deck at home, Debra Likes – who goes by Debbie – decided she’d had enough and would finally see her primary care doctor. She had been ignoring a mole on her left calf for more than a year as she watched it slowly transform from a round...

Read More

7200 Miles for 7200 Lives Lost: Cycling and Community Building After a Melanoma Diagnosis

By Renee Orcione, MRA Digital Engagement & Communications Manager | 23 February 2022 In Allies & Partnerships, Melanoma Stories

Last year in the US, there were an estimated 7,180 deaths from melanoma. For melanoma patient and competitive cyclist Bill Evans, this number is on his mind every single day. Two years into his own journey with advanced melanoma, Bill is raising awareness and funds for melanoma research through cycling, with a goal of completing one mile for every life lost to the disease over the course of a year.

Read More

Preventing Melanoma Among Hispanic Americans

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 22 February 2022 In Melanoma Stories, Prevention, Science

Dr. Costello’s online platform aims to teach participants about the risk factors for melanoma, what it looks like, and how they can screen themselves for concerning lesions. Costello’s program launched in February, 2022; and he hopes to get 30,000 people to participate in the 40-minute curriculum by the end of May 2022.

Read More

New Research Says Immunotherapy Should be First-Line Therapy for Patients with BRAF-Mutant Melanoma

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 2 February 2022 In News, Science, Treatment

While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.

Read More

MRA Celebrates Approval of Tebentafusp - First Drug for Metastatic Uveal Melanoma

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 26 January 2022 In News, Treatment

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food and Drug Administration (FDA) decision to approve the first-ever therapy for metastatic or unresectable uveal melanoma.

Read More